In conclusion, by repressing ABCB1, increasing chemosensitivity and reducing cancer stemness, we speculate inhibition of ROR1, a cancer-specific receptor, in combination with chemotherapy, represents a viable therapeutic strategy for chemoresistant breast cancer and other ROR1-expressing malignancies. Here, ABCB1 is linked to breast cancer.